Research programme: acute pain therapeutics - New River Pharmaceuticals

Drug Profile

Research programme: acute pain therapeutics - New River Pharmaceuticals

Latest Information Update: 10 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator New River Pharmaceuticals
  • Class Morphine derivatives
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Acute pain

Most Recent Events

  • 21 Feb 2008 Discontinued - Preclinical for Acute pain in USA (PO)
  • 12 Aug 2005 New River Pharmaceuticals initiates clinical trials of NRP 290 for acute pain in the USA
  • 28 Jun 2005 New River files an IND application for NRP 290 as a treatment for acute pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top